The impact of KRAS mutations on the clinical outcome and immune response following immunotherapy for pancreatic cancer is a research paper published in Annals of Pancreatic Cancer (2024). On theSindex it has a DataRank of 0.251. It has been cited 4 times, with 4 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.241
From this paper's citation signal
Citation Network Contribution
9.82 × 10⁻³
From 1 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 4 citers.
NCI NIH HHS
Grant: P01 CA247886
NCI NIH HHS
Grant: R01 CA169702
NCI NIH HHS
Grant: R01 CA197296
NCI NIH HHS
Grant: P30 CA006973
NCI NIH HHS
Grant: P50 CA062924
National Institutes of Health
Grant: 5R01CA169702-05
Annexin A2 as a mediator of pancreatic cancer metastases
National Institutes of Health
Grant: 5P50CA062924-25
SPORE in Gastrointestinal Cancers
National Institutes of Health
Grant: 5R01CA197296-05
Reprogramming the pancreatic tumor microenvironment with immunotherapy
National Institutes of Health
Grant: 3P30CA006973-53S2
Regional Oncology Research Center
FWCI
0.91
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals